Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 190INDUSTRY 114NIH 18NETWORK 11OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 4Gynecologic 3Breast 3Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Metastatic 1Meningeal Carcinomatosis 1EGFR Positive Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 13Cisplatin 12Carboplatin 12Drug Therapy 10Gemcitabine 8Gefitinib 8Docetaxel 8camrelizumab 5apatinib 5Radiotherapy 5Paclitaxel 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Endostatins 5tislelizumab 4pembrolizumab 4endostar protein 4Simvastatin 4Bevacizumab 4anlotinib 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Etoposide 3toripalimab 2surufatinib 2olaparib 2durvalumab 2atezolizumab 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Bevacizumab × Thoracic × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Cancer Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03126799 2022-04-06

AvaTa

National Cancer Center, Korea

Phase 2 Unknown
128 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT03240549 2017-08-07

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Beijing Hospital

Phase 2 Unknown
159 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡